Comparative in vivo efficacies of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 5, 2012, Pages 2342-2346

  Tessier, Pamela R ^a   Keel, Rebecca A ^b   Hagihara, Mao ^a   Crandon, Jared L ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

^b CALIFORNIA NORTHSTATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; TEDIZOLID; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; COLONY FORMING UNIT; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; EPITHELIUM; IMMUNOCOMPETENCE; IN VITRO STUDY; IN VIVO STUDY; LUNG FLUID; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL;

ACETAMIDES; ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, INBRED BALB C; OXAZOLIDINONES; PNEUMONIA, STAPHYLOCOCCAL; SURVIVAL RATE; TETRAZOLES; VANCOMYCIN;

EID: 84860162874     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06427-11     Document Type: Article

References (42)

1. Bien P, De Anda C, Prokocimer P. 2010. Microbial efficacy of torezolid phosphate in patients with complicated skin and skin structure infections, abstr F-1592. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
2. Betriu C, et al. 2010. Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain. Antimicrob. Agents Chemother. 54:2212-2215.
3. Boucher HW, Corey GR. 2008. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 46(Suppl. 5):S344 -S349.
4. Bozdogan B, Appelbaum PC. 2004. Oxazolidinones: activity, mode of action, and mechanism of resistance. Int. J. Antimicrob. Agents. 23:113-119. (Pubitemid 38175391)
5. Brown SD, Traczewski MM. 2010. Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges. Antimicrob. Agents Chemother. 54:2063-2069.
6. Butterfield JM, et al. 2011. Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding. Antimicrob. Agents Chemother. 55:4277- 4282.
7. Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, approved standards, eighth ed. CLSI document M07-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Conte JE, Jr, Golden JA, Kipps J, Zurlinden E. 2002. Intrapulmonary pharmacokinetics of linezolid. Antimicrob. Agents Chemother. 46:1475-1480. (Pubitemid 34415331)
9. Crandon JL, Kuti JL, Nicolau DP. 2010. Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin- resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model. Antimicrob. Agents Chemother. 54:5115-5119.
10. da Silva Coimbra MV, et al. 2003. Clonal spread of methicillin-resistant Staphylococcus aureus in a large geographic area of the United States. J. Hosp. Infect. 53:103-110. (Pubitemid 38002066)
11. De Anda C, Das A, Fang E, Prokocimer P. 2011. Acute bacterial skin and skin structure infection (ABSSI) dose-ranging phase 2 tedizolid phosphate (TR-701) study: assessment of efficacy with new FDA guidance, abstr L1-1496. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
12. Deleo FR, Otto M, Kreiswirth BN, Chambers HF. 2010. Community-associated meticillin-resistant Staphylococcus aureus. Lancet 375:1557-1568.
13. Diekema DJ, et al. 2001. Survey of infections due to Staphylococcus species: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis. 32(Suppl 2):S114 -S132.
14. Drusano GL, Liu W, Kulawy R, Louie A. 2011. Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model. Antimicrob. Agents Chemother. 51:5300 -5305.
15. Food and Drug Administration U. S. Department of Health and Human Services. 1998. Guidance for industry. Developing antimicrobial drugs - general considerations for clinical trials. Drug Information Branch, Division of Communications Management, Rockville, MD. http://www.fda.gov/cder/guidance/dft. pdf.
16. Housman ST, et al. 2011. Pulmonary disposition of tedizolid following once-daily oral 200 mg tedizolid phosphate in healthy adult volunteers. abstr A1-1747. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
17. Keel RA, Crandon JL, Nicolau DP. 2011. Pharmacokinetics and pulmonary disposition of tedizolid and linezolid in three murine models, abstr A1-1746. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
18. Kim A, Banevicius MA, Nicolau DP. 2008. In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. Antimicrob. Agents Chemother. 52:2497-2502. (Pubitemid 351915681)
19. Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG. 2004. Clinical cure and survival in Gram-positive ventilatorassociated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Int. Care Med. 30:388 -394.
20. Koomanachai P, Crandon JL, Banevicius MA, Peng L, Nicolau DP. 2009. Pharmacodynamic profile of tigecycline against methicillinresistant Staphylococcus aureus in an experimental pneumonia model. Antimicrob. Agents Chemother. 53:5060 -5063.
21. Laohavaleeson S, Tessier PR, Nicolau DP. 2008. Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains. Antimicrob. Agents Chemother. 52:2389 -2394.
22. Lodise TP, et al. 2011. Penetration of vancomycin into epithelial lining fluid in healthy volunteers. Antimicrob. Agents Chemother. 55:5507-5511.
23. Moran GJ, et al. 2006. Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. 355:666-674.
24. Müller M, de la Peña A, Derendorf H. 2004. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob. Agents Chemother. 48:1441-1453. (Pubitemid 38544345)
25. Muñoz KA, et al. 2010. Improved pharmacokinetics of the novel oxazolidinone antibiotic torezolid phosphate compared to linezolid in healthy subjects, abstr P-1594. Abstr. 50th Annu. Intersci. Conf. Antimicrob. Agents Chemother., Boston, MA, 12 to 15 September, 2010.
26. Pichereau S, et al. 2009. Comparative pharmacodynamics of novel oxazolidinone, torezolid phosphate (TR-701), against S. aureus in the neutropenic murine pneumonia model, abstr A1-1939. Abstr. 49th Instersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA, 12 to 15 September 2009.
27. Pichereau S, Rose WE. 2010. Invasive community-associated MRSA infections: epidemiology and antimicrobial management. Expert Opin. Pharmacother. 11:3009 -3025.
28. Pletz MW, Burkhardt O, Welte T. 2010. Nosocomial methicillinresistant Staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? Comparison of pharmacology and clinical efficacy. Eur. J. Med. Res. 15:507-513.
29. Prokocimer P, et al. 2011. Phase 2, randomized, double-blind, doseranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob. Agents Chemother. 55:583-592.
30. Rodvold KA, Gotfrield MH, Loutit JS, Porter SB. 2004. Plasma and intrapulmonary concentrations of oritavancin and vancomycin in normal healthy adults, abstr O254. Clin. Microbiol. Infect. 10(Suppl 3):44.
31. Sakoulas G, Moellering RC, Jr. 2008. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin. Infect. Dis. 46:S360 -S367.
32. Salerno D, Vahid B, Marik RE. 2007. Methicillin-resistant Staphylococcus aureus pneumonia after thoracic surgery: successful treatment with linezolid after failed vancomycin therapy. Ann. Thorac. Surg. 83:1888 -1891.
33. Shorr AF, et al. 2010. Clinical and economic outcomes for patients with health care-associated Staphylococcus aureus pneumonia. J. Clin. Microbiol. 48:3258 -3262.
34. Shorr AF, Combes A, Kollef MH, Chastre J. 2006. Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilatorassociated pneumonia, despite initially appropriate antibiotic therapy. Crit. Care Med. 34:700 -706.
35. Stein GE, Wells EM. 2010. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillinresistant Staphylococcus aureus: vancomycin and linezolid. Curr. Med. Res. Opin. 26:571-588.
36. Sugihara K, et al. 2010. In Vivo pharmacodynamic activity of tomepenem (formerly CS-023) against Pseudomonas aeruginosa and methicillinresistant Staphylococcus aureus in a murine thigh infection model. Antimicrob. Agents and Chemother. 54:5298 -5302.
37. Tobin CM, Sunderland J, White LO, MacGowan AP. 2001. A simple, isocratic high-performance liquid chromatography assay for linezolid in human serum. J. Antimicrob. Chemother. 48:605- 608.
38. Trius. 15 March 2010. Investigator's brochure. TR-701 FA for oral and IV administration, 4th ed. Trius Therapeutics, Inc., San Diego, CA.
39. Wunderink RG, Mendelson MH, Fabian TC, May AK, Bhattacharyya Leeper HKV, Solomkin JS. 2008. Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus. Chest 134:1200 -1207.
40. Wunderink RG, Rello J, Cammarator SK, Croos-Dabrera RV, Kollef MH. 2003. Linezolid vs. vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124:1789 -1797.
41. Yoon YK, Kim JY, Park DW, Sohn JW, Kim MJ. 2010. Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin. J. Antimicrob. Chemother. 65:1015-1018.
42. Ziglam HM, Baldwin DR, Daniels I, Andrew JM, Finch RG. 2002. Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg oral dose in patients undergoing fibre-optic bronchoscopy. J. Antimicrob. Chemother. 50:1011-1015. (Pubitemid 36032825)